GLP-1 obesity medications, such as Ozempic and Wegovy, play a significant role in weight management, but their effectiveness varies among individuals. Researchers at the University of Alberta are exploring the impact of energy metabolism and individual factors on the success of…
The shift from injectable GLP-1 medications to oral pills presents a significant opportunity to improve diabetes and obesity treatment accessibility, particularly in the Global So…
This article explores the connection between GLP-1 medications, which aid in weight loss, and the importance of protein intake for preserving muscle mass. It highlights research f…
This article discusses the potential risks associated with discontinuing GLP-1 medications like Ozempic and Zepbound, as outlined by Dr. Frank Dumont. Patients may experience rene…
Dr. Ann Nainan from Medicspot provides a three-step plan to help individuals manage weight regain after discontinuing weight-loss injections such as Wegovy and Mounjaro. She empha…
Researchers at the Weizmann Institute of Science have identified the protein MTCH2, which plays a critical role in determining whether cells burn fat or store it. Disabling this p…
As GLP-1 medications like Ozempic and Mounjaro gain popularity for managing diabetes and obesity, it's crucial to understand their nutritional implications. This article explores…
A recent study reveals that GLP-1 medications like Ozempic and Wegovy are changing the types of food people buy, leading to healthier choices. The research analyzed nearly 2 milli…
A recent Phase 3 trial of the experimental obesity medication retatrutide demonstrated an average weight loss of 25% at the highest dose over 80 weeks, along with improvements in…
Eli Lilly's experimental obesity treatment, combining eloralintide and Mounjaro, has demonstrated an average weight loss of 23% in individuals with diabetes, highlighting its pote…
Recent research suggests that Ozempic-like medications, which include semaglutide, may influence alcohol cravings and consumption patterns. While some studies indicate a reduction…
A recent study published in the journal Childhood Obesity reveals that approximately 16.8% of children aged 10 to 17 who began treatment with GLP-1 receptor agonist medications de…
Yale researchers have revealed a new certification process for anti-aging treatments that mandates diet and prescription medications while deeming popular supplements ineffective,…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…